

NOV. 4. 2003 5:40PM

GLAXO WELLCOME

NOV 04 2003

NO. 1280 P. 1

OFFICIAL



GlaxoSmithKline

FAX

To Examiner Jeffrey S. Parkin, Group 1648

Company USPTO

Fax 703-872-9306

From Marjorie J. Pfeiffer

Tel 1-919-483-9038; Facsimile: 1-919-483-7988

E-mail [Mjp14849@gsk.com](mailto:Mjp14849@gsk.com)

Date November 4, 2003 Pages including cover 5

Subject Response to Election/Restriction Requirement

GlaxoSmithKline  
PO Box 13398  
Five Moore Drive  
Research Triangle Park  
North Carolina 27709

Tel: 919 483 2100  
[www.gsk.com](http://www.gsk.com)

Re: Application of James Martin LENHARD  
U.S. Serial No.: 09/889,471; Filed: July 17, 2001  
Title: *Methods of Screening Protease Inhibitors,  
Of Inducing Mice Susceptible to HIV Protease  
Inhibitor-Induced Dyslipidemia, and Genes  
Associated Therewith*  
Attorney Docket No. PU3610USw


Attached:

1. Response to Restriction Requirement (2 pages)
2. Petition for Extension of Time (in duplicate)

CERTIFICATE OF MAILING (37 CFR 1.8)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being facsimile transmitted or deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

Date: November 4, 2003

  
Marjorie J. Pfeiffer

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

NOV 04 2003

Attorney Dkt. No. PU3610USw

**OFFICIAL**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: James Martin LENHARD

Serial No.: 09/889,471

Unit: 1648

Filed: July 17, 2001

Examiner: Parkin, Jeffrey S

For: *Methods Of Screening Protease  
Inhibitors, Of Inducing Mice  
Susceptible To HIV Protease  
Inhibitor-Induced Dyslipidemia,  
and Genes Associated Therewith*

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**RESPONSE TO ELECTION/RESTRICTION REQUIREMENT**

Sir:

This paper is submitted in response to the Office Action mailed September 5, 2003 (Paper No. 5) for which a one month shortened statutory period to respond was set. Accordingly, a Petition and Fee for a one-month Extension of Time is submitted herewith, extending the period of time for response to November 5, 2003. The Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392. Early examination of the application on the merits is earnestly solicited.

**REMARKS**

Claims 1-4, 26-36, 41-48, 55, 56, 58-63 and 71-181 are pending in this application. The Examiner has required restriction to one of 13 groups. In response to such restriction Applicants wish to proceed as follows.

Applicants elect without traverse Group I drawn to methods of screening retroviral therapeutic agents (RTAs) for their capacity to affect lipodystrophy by measuring the inhibition of adipogenesis, claims 1, 2 and 71-90, for proceeding with prosecution on the merits.